Study of HMPL-306 for brain tumors with IDH mutations
Part of Cancer clinical trials.
This trial tests a new drug, HMPL-306, for people with a type of brain tumor (glioma) that has an IDH1 or IDH2 mutation. The goal is to see if the drug can shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a glioma brain tumor with an IDH1 or IDH2 gene mutation.
- You are at least 18 years old.
- You have not received any previous IDH inhibitor treatment.
- You are able to perform daily activities with minimal help (KPS score 80% or higher).
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HMPL-306 in people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It is for patients whose leukemia cells have a specific change in the IDH1 or IDH2 gene.
This trial tests a new pill called TQB3454 for people with advanced solid tumors, especially brain tumors (gliomas) or bile duct cancers that have a specific IDH1 gene mutation. It aims to see if the drug can shrink tumors and improve outcomes.
This study uses a special type of PET/MRI scan to look for a common genetic change (IDH mutation) in brain tumors (gliomas). The goal is to improve how doctors diagnose and treat these tumors.
This trial uses a special PET scan to see how IDH-mutant gliomas respond to treatment. It may help your doctor better track your tumor's activity.
This study tests a combination of two drugs (vorasidenib and lomustine) for people with a specific type of recurrent brain tumor that has an IDH mutation. The goal is to see if this combination can slow tumor growth better than standard treatments.
This study looks at leftover tumor cells in people with a type of brain tumor called IDH-mutant glioma. Doctors want to learn how many tumor cells remain after treatment by testing tissue from a biopsy or surgery. This may help improve future care.
Hear when a new Gliomas Harboring IDH1 and/or IDH2 Mutations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.